Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 431 participants.
Also called NCT03284255
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 431 participants
- Sponsor
- Registry
-
NCT03284255
-
- Other papers using this trial's data
- A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03284255. Randomized; no masking; primary purpose treatment. Start 2017-09-11 (actual); primary completion 2020-08-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
- Condition
- Coronary Artery Disease
- Condition
- Antineoplastic Agents
- Intervention (Device)
- study group
- Intervention (Device)
- control group
- Lead sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
- Collaborator
- CCRF Inc., Beijing, China
Record details
- Record id
cardio:ct-nct03284255- Content hash
fa569cdb0775b0388507abd0027d70d202b1179e94b06079bd6b4b9034af260a